Monkasta (Montelukast)

Montelukast, the active ingredient in Monkasta, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Monkasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monkasta (montelukast) acts on the leukotriene pathway to control chronic airway disorders. - Asthma: improves control of persistent asthma and reduces exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Adverse reactions may range from mild to serious and should be monitored during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: nasopharyngitis or common cold symptoms. - Abdominal pain: discomfort or cramping in the stomach area. - Diarrhoea: loose stools occurring intermittently. - Cough: non‑productive cough episodes. - Rash: mild skin erythema or itching.

Serious or Rare Side Effects: - Neuropsychiatric events: agitation, depression or suicidal thoughts. - Angioedema: swelling of lips, tongue or face. - Hepatotoxicity: elevated liver enzymes indicating liver stress. - Anaphylaxis: severe, life‑threatening allergic reaction. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.

Before initiating therapy, consider the following safety measures. - Pregnancy: discuss potential risks with a healthcare professional; data are limited. - Breastfeeding: evaluate benefits versus possible infant exposure. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant medications: review all current drugs for possible interactions. - Age restrictions: ensure appropriate dosing for pediatric patients as prescribed. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; monitoring is advised.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: strong enzyme inducer that can lower therapeutic effect.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): potential for neuropsychiatric side effects. - Warfarin: occasional reports of altered INR; monitor coagulation. - Beta‑agonists: additive bronchodilator effect may increase risk of tremor. - Antihistamines: combined use may increase sedation in sensitive individuals.